David M. Livingston is at the Dana-Farber Cancer Institute and The Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA. David_Livingston@dfci.harvard.edu
Sporadic breast cancers only rarely contain BRCA2 or BRCA1 mutations, despite the presence of such mutations in inherited breast and ovarian cancers. The identification of a new binding partner for BRCA-2 sheds light on this incongruity.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
